Biotech Stocks Sell-Off On Profit Taking: Traders Rule
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down 4.25% and Vivus (VVUS) down...
Reporting from the JPMorgan 29th Annual Healthcare Conference 2011
J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel. Topcoats were the unlikely...
Rayno Life Science Portfolio Review:Celera(CRA),Qiagen(QGEN),and Gilead(GILD)
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the one billion range but the...
Rayno Snow Blog: High and Dry in the West
Did you ski a lot in December? We hope so because January has not delivered much precip since January 2. Mammoth had 13 in on Jan 1 and 2 but scant since that time. Our associate at Big Mountain Resort in Montana complains of rain and fog yesterday but a few flakes may fall today. The culprit...
2011 Review of Rayno Life Science Portfolios Next Week
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is "don't fight the FED, don't fight the tape". The large cap laggards...